Welcome to our dedicated page for NantHealth news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NantHealth stock.
Company Overview:
NantHealth Inc. (symbol: NH) is a pioneering healthcare technology company that is transforming the landscape of personalized healthcare. The company's mission is to optimize patient outcomes and enable value-based care through advancements in technology and precision medicine.
Core Business and Offerings:
NantHealth integrates novel diagnostics with large-scale biometric and phenotypic data to deliver truly personalized healthcare solutions. By adopting a systems-based approach, NantHealth enhances treatment decisions for critical illnesses, effectively improving patient outcomes.
Recent Achievements:
The company has made significant strides in deploying its precision medicine platforms, harnessing biometric and phenotypic data. These achievements underscore NantHealth's commitment to pushing the boundaries of personalized healthcare.
Current Projects:
NantHealth is actively involved in developing and refining its healthcare platforms. The focus is on integrating advanced diagnostics with data analytics to provide actionable insights that guide treatment options, ensuring better care for patients.
Financial Condition:
While specific financial details fluctuate with market activities and quarterly reports, NantHealth remains dedicated to its financial health and sustainable growth, continually seeking to advance its mission and technology.
Partnerships:
NantHealth collaborates with various healthcare providers, research institutions, and technology companies to enhance its offerings and expand its impact on the healthcare sector.
Significance:
NantHealth's unique approach to integrating diagnostics and data analytics sets it apart in the healthcare industry. Their commitment to precision medicine has made them a significant player in the quest for more effective and personalized treatments for critical illnesses.
NantHealth Inc. (NASDAQ: NH) has been awarded full URAC accreditation for Health Utilization Management for its Eviti Connect platform, extending accreditation through September 1, 2025. This certification acknowledges NantHealth's compliance with recognized standards in healthcare quality and management. The URAC accreditation process validates the effectiveness of their processes, enhancing patient outcomes and demonstrating the company's commitment to quality healthcare delivery.
NantHealth reported Q2 2022 net revenue of $16.5 million, a slight increase from $16.1 million in Q2 2021, marking continued growth for the third consecutive quarter. The company maintained a gross margin of 55%. Despite this growth, operating expenses rose, with SG&A increasing to $14 million and R&D expenses reaching $5.9 million. Net loss narrowed to $12.5 million or $0.11 per share, an improvement from $15.3 million or $0.13 per share a year earlier. Cash reserves stood at $5.7 million.
NantHealth, Inc. (NASDAQ: NH) will report its financial results for Q2 2022 on August 4, 2022, post-market. The company specializes in transforming complex data into actionable insights for various sectors, including healthcare and telecommunications. A conference call is scheduled on the same day at 1:30 p.m. PT to discuss the performance.
Interested participants can join by calling 800-771-6692 in the U.S. and Canada or 212-231-2907 internationally. The call will also be streamed live on their website.
The OpenNMS Group, a subsidiary of NantHealth (NASDAQ: NH), announced the release of OpenNMS Horizon 30 and OpenNMS Plugin API 1.0. Horizon 30 introduces enhanced NetFlow capabilities including real-time alarm generation and centralized device configuration backups. Key features also include improved device inventory workflows, OpenAPI support, and an updated Grafana plugin. The Plugin API fosters a stable development ecosystem for building integrations and plugins, ensuring compatibility with future releases. These updates aim to enhance network monitoring and performance for enterprise users.
NantHealth, Inc. (NASDAQ: NH) reported Q1 2022 net revenue of $16.4 million, a slight increase from $16.2 million in Q1 2021. Gross profit remained stable at 56% of total revenue. The company faced rising expenses, with SG&A increasing to $15.0 million from $12.5 million, and R&D expenses rising to $5.7 million. Net loss from continuing operations was $16.0 million or $0.14 per share, compared to a net loss of $15.4 million or $0.14 per share in the previous year. Cash reserves stood at $16.1 million.
NantHealth, Inc. (NASDAQ: NH) will report its 2022 first quarter financial results on May 5, 2022, after market close. Following the announcement, management will conduct a conference call at 1:30 p.m. PT to discuss performance. Interested parties can join via phone or through an online broadcast.
The company specializes in enterprise solutions that convert complex data into actionable insights for industries such as healthcare and telecommunications, offering solutions for real-time coverage decision support and data analysis.
OpenNMS Group, a subsidiary of NantHealth (NASDAQ: NH), has released the OpenNMS Meridian 2022, enhancing security and functionality in its open-source network monitoring platform. Key updates include improved security by enabling non-root user access, faster analytics processing, simplified communication protocols, enhanced geolocation features, and an expanded set of REST APIs for integration. OpenNMS is also focusing on cybersecurity measures, aligning with ISO 27001, and adopting penetration testing in development processes. These updates aim to meet enterprise demands for security and compliance.
NantHealth, a provider of enterprise solutions, announced participation in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:50 p.m. ET. The event will highlight NantHealth's capabilities in transforming complex data into actionable insights for various industries, including healthcare and life sciences. A live audio webcast will be available on NantHealth's corporate website for interested investors. This engagement underscores NantHealth's commitment to innovation in data solutions and security.
NantHealth announced a significant multi-year renewal agreement with a leading nonprofit health plan, enhancing its Eviti Connect for Oncology platform. This expansion introduces radiation therapy validation and care navigation services, impacting over two million members across six states. The new services aim to streamline cancer treatment processes, improve member experiences, and reduce administrative burdens on healthcare providers. The agreement underscores NantHealth's commitment to delivering evidence-based, patient-centric care.
FAQ
What does NantHealth Inc. do?
What is NantHealth's mission?
What recent achievements has NantHealth made?
What are some of NantHealth's current projects?
Who are NantHealth's partners?
How does NantHealth impact the healthcare industry?
What makes NantHealth's approach unique?
Is there a focus on value-based care at NantHealth?
Where can I find more information about NantHealth?
How can I stay updated on NantHealth's latest developments?
